Funko (FNKO) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Rob Jeffrey - Director of Investor RelationsCynthia Williams - CEO & DirectorYves LePendeven - CFOAntares Tobelem - Equity Research AssociateKeegan Cox - Research Associate Operator Good afternoon, and welcome to Funko's twenty twenty five First Quarter Financial Results Conference Call. At this time, all participants are in listen only mode. Later, we will conduct a question and answer session and instructions will follow at t ...

Rocket Companies (RKT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Sharon Ng - VP of IRVarun Krishna - Chief Executive OfficerBrian Brown - CFO & TreasurerRyan Nash - Managing Director - Regional Banks & Consumer FinanceMark Devries - DirectorBose George - Managing DirectorJeff Adelson - Executive Director Conference Call Participants Douglas Harter - Equity Research AnalystMihir Bhatia - Equity Research Analyst Operator Thank you for standing by, and welcome to The Rocket Company's ...

Financial Data and Key Metrics Changes - First quarter revenue was $1,040 million, down 1.4% year over year, with constant currency revenue roughly flat [20][19] - Non-GAAP EPS was $0.97, at the upper end of guidance [19][27] - Non-GAAP gross margin increased by 30 basis points year over year to 67.4% [25] - Non-GAAP operating margin was 20.4% in Q1 [27] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $696 million, growing approximately 1% year over year [20] - Sequencing instruments revenue was approximately flat year over year at $109 million [23] - Sequencing service and other revenue was down approximately 5% year over year to $142 million [24] Market Data and Key Metrics Changes - Clinical business showed mid single-digit growth, while research business was down in the high mid to high single-digit range [50][49] - Approximately 68% of high throughput gigabases shipped were on the NovaSeq X Series [22] - Over 50% of clinical volumes are now on the NovaSeq X Series [22] Company Strategy and Development Direction - The company aims for high single-digit revenue growth and 500 basis points margin expansion by 2027, excluding Greater China [10] - A $100 million cost reduction program was initiated to address challenges from China and research funding uncertainty [12] - The company is focusing on advancing the Multiomics ecosystem and has a strong innovation pipeline [9][17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged macroeconomic challenges but expressed confidence in the company's resilience and growth potential [7][10] - The company is revising guidance to reflect headwinds from China and research funding uncertainties [11][29] - Management emphasized that the challenges are transitory and will not define long-term success [10] Other Important Information - The company is engaging with regulatory authorities in China for potential solutions to support a sustainable long-term presence [11] - The impact of new tariffs is estimated to be approximately $85 million for 2025, with actions being taken to mitigate this [35][36] Q&A Session Summary Question: What is the outlook for revenue growth and margin expansion? - Management believes that revenue growth will rebound and margins will expand above 25% in the future, despite current challenges [42] Question: What are the clinical and research revenue growth rates? - Clinical revenue grew mid single digits, while research revenue declined in the high mid to high single-digit range [50][49] Question: How is the company managing risks related to China? - The company has taken actions to offset potential risks from China, including a $100 million cost reduction program [46] Question: How are tariffs impacting demand? - No significant change in customer behavior was observed in Q1 due to tariffs, but future impacts are anticipated [68][70] Question: What are the assumptions behind the revenue guidance? - The guidance reflects a 15% decline in research revenue, offset by stronger clinical performance [76][78]

Financial Data and Key Metrics Changes - The company reported revenue of $104 million for Q1 2025, which is essentially flat compared to the previous year, despite the expiration of the alternative fuel tax credit that contributed $5.4 million to last year's revenue [20][21]. - Adjusted EBITDA for Q1 2025 was $17.1 million, up from $12.8 million in the same quarter last year, driven by strength in the fuel distribution business [23][24]. - The company ended the quarter with $227 million in cash, reflecting a $9 million increase since the beginning of the year [7]. Business Line Data and Key Metrics Changes - Renewable natural gas (RNG) sales volumes were reported at 51 million gallons, lower than Q1 2024 due to reduced supply from third-party producers affected by weather and operational issues [6][7]. - Despite lower RNG sales volumes, the company maintained strong demand from fleet customers in the refuse, transit, and trucking sectors [8][10]. Market Data and Key Metrics Changes - The company noted that tariffs have minimal direct impact on its business, although they create uncertainty for customers in the heavy-duty trucking sector [8][10]. - The market dynamics for RNG are favorable, with a strong demand for low-carbon fuels, particularly in the heavy-duty trucking market [12][30]. Company Strategy and Development Direction - The company is focused on expanding its RNG production and distribution capabilities, with ongoing projects in dairy RNG production expected to come online by the end of the year [17][18]. - The company is maintaining its full-year financial outlook and capital expenditure guidance, indicating confidence in its growth trajectory [10][18]. Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding achieving the 2025 guidance, citing potential impacts from tariffs and economic conditions affecting truck purchases [28][29]. - The company believes RNG is well-positioned as a viable alternative fuel amidst changing regulatory landscapes and customer preferences for low-carbon solutions [30][51]. Other Important Information - The company resumed its share repurchase program in late March, indicating confidence in its stock valuation and financial health [18]. - The expiration of the alternative fuel tax credit and the introduction of the Renewable Natural Gas Incentive Act are significant developments that could impact future financial results [15][16]. Q&A Session Summary Question: What would take you to the lower end and what could take you to the upside regarding the 2025 guidance? - Management indicated that clarity on tariffs and customer purchasing behavior in the trucking sector would influence the outlook, with optimism for increased truck purchases as market conditions stabilize [28]. Question: How do you see pricing shaking out for the remainder of the year? - Management expects steady pricing, supported by a favorable spread between oil and natural gas, despite the absence of the alternative fuel tax credit [32][34]. Question: Can you provide an update on RNG facilities and their timelines? - Management reported that one RNG facility is producing well, while others are progressing but not yet at desired levels, with expectations for improvement by the end of the year [56][58]. Question: What is the status of partnerships with Total, BP, and Chevron? - The company maintains strong relationships with these partners, with ongoing projects and a focus on RNG development [87][89]. Question: What is the outlook for the 45Z tax credit? - Management noted that the impact of the 45Z tax credit is uncertain, but discussions are ongoing, and it could be a significant contributor if finalized favorably [94][98].

Financial Data and Key Metrics Changes - Adjusted property EBITDA at Silver Slipper grew by 21% year-over-year despite a slight decline in property revenue, with expectations of reaching mid-teens in adjusted EBITDA for the current year [6][7] - American Place achieved an all-time record gaming revenue month in March, crossing $10 million for the first time, with continued growth in the guest database [12][13] - The company extended the maturity date of its revolver from March 2026 to January 2027 and reduced the revolver balance to $25 million [14] Business Line Data and Key Metrics Changes - At Chamonix and Bronco Billy's, revenue grew by 34% in the first quarter, although EBITDA remained slightly negative due to expenses growing at a similar pace [9] - Significant cost savings were identified across various departments, including over $1.5 million in food and beverage and $800,000 from reduced overtime costs [10][11] Market Data and Key Metrics Changes - The company has doubled its gaming market share without significantly impacting other operators, indicating an undersaturated market [10] - The gaming revenue in the market is expected to grow as the company continues to attract customers who historically have not visited [10] Company Strategy and Development Direction - The company is focusing on management upgrades and operational improvements across its properties, with new general managers appointed to key locations [5][16] - Plans are underway to open a permanent facility for American Place, with a target to break ground in the second half of the year [26][28] - The company is exploring relocation opportunities for Rising Star to capitalize on more favorable market conditions in larger cities [55][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability in Q2 and expects continued revenue growth as properties mature [19][23] - The company is monitoring the bond market for refinancing opportunities to fund the construction of the permanent American Place [35][123] - Management acknowledged the challenges posed by tariffs but indicated potential benefits from a recession in terms of construction costs [43][44] Other Important Information - The company has completed the sale of Stockman's and is now focusing on its three primary properties [13][51] - A new Chief Marketing Officer has been hired to enhance marketing strategies, particularly in Colorado [12][15] Q&A Session Summary Question: Update on Colorado's performance and expenses - Management expects Q2 to be more profitable than Q1, with continued revenue growth and identified cost-saving opportunities [19][20] Question: Strategic outlook for the portfolio post-sale of Stockman's - The company views its three main properties as a strong foundation and is cautious about new acquisitions, focusing on existing opportunities [51][64] Question: Trajectory of sports wagering contracts - The market is dominated by a few large players, making it challenging to replace lost contracts, but the company is exploring options [66][68] Question: Timeline for reaching $20 million EBITDA - Management aims for a five-year timeline to exceed $20 million in EBITDA, with expectations of significant revenue growth from the permanent facility [72][74] Question: Confidence in new management teams - Management believes that fresh perspectives from new hires will lead to improved performance, citing past successes of new leadership [83][89] Question: Changes in customer visitation and spending - No significant changes in visitation frequency or spending have been noted, with some fluctuations attributed to weather and market conditions [110][114] Question: Capital expectations and liquidity for the second half of the year - The company is in good liquidity shape and plans to refinance existing debt while funding the construction of the permanent facility [121][123]

Research Frontiers (REFR) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Joseph Harary - CEO, President, General Counsel, Corporate Secretary & Director Conference Call Participants None - Analyst Operator Afternoon, and welcome to the Research Frontiers' Investor Conference Call to discuss the First Quarter of twenty twenty five Results of Operations and Recent Developments. The company will be answering many of the questions that were e mailed prior to the conference call, either in t ...

ICU Medical (ICUI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants John Mills - Managing PartnerVivek Jain - Chairman & Chief Executive OfficerBrian Bonnell - Chief Financial OfficerJayson Bedford - Managing Director - Medical TechnologyJoseph Conway - Equity Research Associate Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystLarry Solow - Partner & Managing director - Equity AnalystMichael Toomey - US Medtech Analyst Operator Good day, and welcome to ...

INmune Bio (INMB) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants David Moss - Chief Financial OfficerRaymond Tesi - CEO & ChairmanMark Lowdell - Chief Scientific Officer & Chief Manufacturing OfficerDenis Reznik - Senior Equity Research AssociateChristopher Barnum - VP - NeuroscienceGeorge Farmer - Managing DirectorLaura Suriel - Equity Research Associate Conference Call Participants Thomas Shrader - MD & Healthcare Analyst Operator Greetings, and welcome to the Immune Bio First Quarter ...

CVRx (CVRX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Michael Vallie - Managing DirectorKevin Hykes - President & CEOJared Oasheim - Chief Financial OfficerMacauley Kilbane - Equity Research AssociateNelson Cox - Equity Research Associate Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRoss Osborn - Director, Lead Research Analyst - MedTech and Diagnostics Operator Standby, your program is about to begin. Good day, everyone, and welcome ...

Lisata Therapeutics (LSTA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants John Menditto - Vice President of Investor Relations & Corporate CommunicationsDavid Mazzo - President and Chief Executive OfficerJames Nisco - SVP of Finance, Treasurer, CAO & Principal Financial & Accounting OfficerKristen Buck - EVP of R&D and Chief Medical OfficerSara Nik - Senior Associate - Equity ResearchPeter Enderlin - Portfolio Manager Conference Call Participants Kemp Dolliver - Director - Research & Se ...